Fanconi anemia (FA) is an autosomal recessive chromosomal instability disorder caused by mutations in one of seven known genes (FANCA,C,D2,E,F,G and BRCA2). Mutations in the FANCA gene are the most prevalent, accounting for two-thirds of FA cases. Affected individuals have greatly increased risks of acute myeloid leukemia (AML). This raises the question as to whether inherited or acquired mutations in FA genes might be involved in the development of sporadic AML. Quantitative fluorescent PCR was used to screen archival DNA from sporadic AML cases for FANCA deletions, which account for 40% of FANCA mutations in FA homozygotes. Four heterozygous deletions were found in 101 samples screened, which is 35-fold higher than the expected population frequency for germline FANCA deletions (Po0.0001). Sequencing FANCA in the AML samples with FANCA deletions did not detect mutations in the second allele and there was no evidence of epigenetic silencing by hypermethylation. However, real-time quantitative PCR analysis in these samples showed reduced expression of FANCA compared to nondeleted AML samples and to controls. These findings suggest that gene deletions and reduced expression of FANCA may be involved in the promotion of genetic instability in a subset of cases of sporadic AML.
Introduction
Fanconi anemia (FA) is an autosomal recessive DNA disorder characterized by hypersensitivity to DNA crosslinking agents. 1 Affected individuals have characteristic congenital abnormalities, develop bone marrow failure at an early age, and have a greatly increased risk of developing myelodysplasia (MDS), acute myeloid leukemia (AML) and solid malignancies.
2-4 A report on 754 FA patients diagnosed over a 20-year period showed that the risks of developing bone marrow failure and MDS or AML by age 40 years were 90 and 33% respectively. 3 A recent survey of cancer incidence in 145 FA patients reported nine cases of myeloid leukemia with a median age-of-onset of 11.3 years, and a ratio of observed to expected cases of 785. 4 Complementation analysis by cell fusion and correction of crosslinker hypersensitivity has delineated at least eight complementation groups; FA-A, B, C, D1, D2, E, F, G, 5 six genes have been cloned, FANCA, C, D2, E, F, G, [6] [7] [8] [9] [10] [11] [12] and a recent report has shown biallelic inactivation of BRCA2 in FA-D1 cell lines. 13 Since the incidence of AML is highly elevated in FA patients, it is possible that inherited or acquired mutations in the FA genes contribute to the etiology of sporadic AML. Epidemiological studies assessing incidence of malignancies (including AML) in FA families have failed to demonstrate an increased incidence in heterozygous individuals. 14, 15 However, it is conceivable that genomic instability may result from a second somatic mutation in an FA carrier or from one or two somatic mutations in a progenitor cell resulting in malignancy. 16 Another chromosome instability syndrome, ataxia telangiectasia (AT) has been implicated in sporadic leukemias; the AT gene, ATM, is frequently deleted or mutated in T-cell prolymphocytic leukemia, [17] [18] [19] and ATM mutations have also been detected in sporadic non-Hodgkin's lymphomas 18 and B-cell chronic lymphocytic leukemia. 20 Moreover, heterozygous carriers of AT mutations have a phenotype at the gene expression level that differs from control individuals. 21 Thus, heterozygosity for an ATM mutation may predispose to these malignancies.
Current evidence regarding the role of FA mutations in sporadic hematological malignancies including AML is limited; an analysis of 79 cases of adult AML for FANCA point mutations found 13 exonic nucleotide changes, none of which led to truncation of FANCA. 22 Five changes were novel missense mutations leading to nonconservative amino-acid substitutions in four cases, none of which was present in 79 normal controls. One additional missense mutation A3982G (causing the aminoacid change T1328A) had previously been reported to be pathogenic, 23 and the other seven nucleotide changes were polymorphisms. A recent analysis of FANCC in 97 cases of sporadic pediatric AML found no evidence of known pathogenic mutations, although one polymorphic variant was present at four-fold greater frequency in the AML cases compared to controls. 24 Xie et al 25 analyzed cellular lysates from 10 sporadic AML cell lines for FANCA, C, F and G protein expression using Western blotting. Aberrant FA protein profiles, including the absence or reduced presence of protein, were observed in five out of the 10 cell lines. In cell lysates from primary AML blasts, 11 out of 15 cases also had aberrant profiles. Further evidence that disruption of the FA pathway may be implicated in the etiology of some sporadic AML cases is provided by Lensch et al, 26 who reported a case of acquired cytogenetic instability in a 68-year-old man with AML and demonstrated FANCA dysfunction in tumor cells, while lymphoblastoid cells from the same individual had normal FANCA function.
The high incidence of AML in FA homozygotes and the evidence for deficiency of FA proteins and their complexes in sporadic AML, 25, 26 have led us to examine the role of inactivation of the FA pathway in the development of sporadic AML. We selected the FANCA gene for analysis since mutations in this gene account for 70% of all cases of FA. The mutation profile of FANCA is highly heterogeneous with over 100 different mutations described, 23, [27] [28] [29] and there is a 40% incidence of large deletions, which remove 1-43 exons from the gene. 28, 30 Screening for these mutations thus accounts for nearly 30% of all FA mutations across all complementation groups. 
Materials and methods

Samples
GAAACACCGGTCACCGTCTGTG 3
0 , reverse 5 0 AGATCCAC-GATTCTTCGCATTGTC 3 0 ). PCRs were performed in 25 ml reactions with 125 ng DNA, 1 Â Taq Polymerase buffer, 200 mM each dNTP and 0.2 mM of each primer. After an initial denaturation at 941C for 3 min 1.5 U Taq DNA Polymerase (Promega, UK) was added (hot start), followed by 22 cycles of 941C for 1 min, annealing at 571C for 1 min, and extension for 2 min at 721C with a final extension for 5 min at 721C. Only 22 PCR cycles were performed to keep the reaction within the exponential phase. 28, 32 The fluorescent products were quantified using an ABI 310 (Applied Biosystems, Warrington, UK) and compared to MPZ. Values were compared to at least two normal control samples and a peak area ratio was calculated for each sample. In samples where the deletion included exon 31, a further QF-PCR biplex assay that amplified FANCA exons 42 and 43 in a single 468 bp fragment (forward 5 0 GCACAGCATG-CAGACTATGG 3 0 ; reverse 5 0 GGCAGGTCCCGTCAGAAGA-GAT 3 0 ) and MPZ was carried out to determine the 3 0 extent of the deletion. Samples in which deletions were found were typed with microsatellite markers, which flanked and were tightly linked to FANCA. Sequencing of the 43 exons of FANCA was undertaken to screen for a second mutation in the nondeleted allele.
Sodium bisulfite sequencing
The sodium bisulfite conversion technique described by Clark et al 33 was used to develop an assay for the methylation status of the FANCA CpG island. Following sodium bisulfite conversion, PCR reactions to amplify the FANCA CpG island sequence were performed on a Techne Genius thermocycler in oil-free 25 ml reactions. A measure of 12.5 ml of sodium bisulfite-converted DNA was added to 12. 
AGAGAAAAAATG-GAAAAAAAA 3
0 ). After an initial denaturation of 5 min at 941C, a touch-down protocol was used: five cycles of 941C for 20 s, 601C for 30 s (reducing by 11C/cycle) and 721C annealing for 40 s, followed by a further 30 cycles of 941C for 20 s, 551C for 30 s, 721C annealing for 40 s (increasing by 2 s with each cycle), and a final extension step of 5 min at 721C. For the second (seminested) PCR, 0.5 ml of the first PCR end-product was transferred to a new 24.5 ml PCR mixture with the same final concentration of reagents as above, but using a different reverse primer (2R, 5 0 GGAAATGAATGGGGTTGGTAATG 3 0 ). The conditions for this PCR were the same as above, but without the initial 5-cycle touch-down step.
The PCR product was purified and sequenced using a commercial sequencing kit (Applied Biosystems, Warrington, UK) according to the manufacturer's instructions. The reverse primer was the same as that used for the second PCR, with a different forward primer (2F, 5 0 GTAGG( T / C )GTATTTTTTAG-GATTAATATG 3 0 ). The resulting amplicon had an expected length of 221 bp and was predicted to contain 24 CpG dinucleotides. The product was cleaned and analyzed using an ABI 310 Genetic Analyzer (Applied Biosystems, Warrington, UK). Sequence data were analyzed using Sequence Navigator software (Applied Biosystems, Warrington, UK), specifically assessing each CpG island to determine whether a thymine was present (indicating that the original cytosine residue was unmethylated), or whether a cytosine was present (indicating methylation). A cell line with extensive methylation of the FANCF promoter was used as a control for the lack of conversion of methylated CpGs by sodium bisulfite.
Real-time quantitative RT-PCR (RQ-PCR)
In order to determine whether FANCA mRNA expression was altered in AML samples with heterozygous FANCA deletions, an RQ-PCR assay was developed using the Taqman technology and an ABI 7700 (Applied Biosystems, Warrington, UK) with methods previously described. 34 Expression of the FANCA exon 19/20 transcript was compared with two different endogenous control genes, ABL and b2-microglobulin (B2M), using published primer and probe sets. Expression of these control genes has been documented as comparable between normal hemopoietic cells and acute and chronic leukemias. 35 Primers and probe sequences for the FANCA amplicon including exons 19 and 20 were: forward primer, 5
0 -CGTCATGGAGGCCAGCA-TAT-3 0 , and reverse primer 5 0 -TGGCAGTAGGTGGAGTAGA-GAG-3 0 , and probe 5 0 -FAM-CCCGCCCTGCTCACACCTCG-TAMRA-3 0 . Plasmid standards for each target gene were generated (FANCA) or obtained commercially (B2M, ABL; Ipsogen, Marseille, France) and serially diluted to encompass the range of expression levels encountered in hemopoietic cells. Gene expression was quantified in terms of normalized copy number (NCN), which was derived from the relevant standard curve. Samples with control gene expression levels outside the normal range as defined previously 35 were deemed to have unsatisfactory RNA and were excluded from the analysis.
Results
FANCA gene dosage analysis and mutation screen
Four of the 101 sporadic AML samples that were tested using the FANCA gene dosage assay were found to have heterozygous deletions in FANCA (see Figure 1 , panel A), and these were analyzed further. In samples 63 and 96, one copy of all the exons tested (5-43) was deleted, and in samples 65 and 83 the deletions were intragenic, and involved exons 19-21 and 11-21 respectively. Microsatellite polymorphism analysis was performed using four markers tightly linked to and flanking the FANCA locus (D16S3074, D16S3026, D16S3121, D16S303) to investigate the extent of the deletions, and all were homozygous (or hemizygous) for the four markers. This reinforced the possibility that, for the two samples where all exons tested were deleted, the deletion could have extended beyond the FANCA gene. The two samples with intragenic deletions were either homozygous for all four markers, or other deletions may have been present in the region (summarized in Figure 1, panel  B) . Clinical and cytogenetic data were available on three samples (Table 1 ) and all three were de novo AMLs; they were classified into FAB groups M1, M2 and M6, and all had complex karyotypes with monosomy 7. All three samples also had 16q abnormalities (FANCA is located on 16q24.3), although none had cytogenetically apparent chromosome deletions of this region.
All 43 exons of FANCA were sequenced in the four samples with deletions to determine whether the remaining allele was inactivated by other classes of mutations. In addition to the coding sequence of each exon, approximately 30 bp of sequence 5 0 and 3 0 to each exon were also analyzed to detect possible splice site mutations. Several polymorphisms but no inactivating mutations were found in these samples. Details of the polymorphisms found are given in Table 2 . The age range of the four patients with deletions was 45-69 years (Table 1) , and as there was no evidence of prior stem cell failure or congenital abnormalities, a primary diagnosis of FA is very unlikely.
FANCA promoter methylation analysis
Methylation of cytosine in CpG islands of the promoter region of genes is a well documented mechanism of silencing tumor suppressor genes in cancer 36 but has not been studied in FANCA to date. The 5 0 region of FANCA contains a CpG island that extends into exon 1, 37 and methylation of this region may provide an alternative mechanism of FANCA gene inactivation. A sodium bisulfite conversion and sequencing assay 33 was developed to detect methylation of the FANCA CpG island. Treatment of DNA with sodium bisulfite converts unmethylated cytosines to uracil while methylated cytosines are unchanged; after PCR, unmethylated cytosines are thus detected as thymines on sequencing. This region, which contains 24 CpG dinucleotides, was analyzed in the four samples with FANCA deletions to establish whether the remaining allele had been silenced by methylation. There was no evidence of cytosine methylation of FANCA in these four samples, or in peripheral blood lymphocytes from three normal individuals.
FANCA gene expression analysis
Since there was no evidence of inactivation of the second allele in the four samples with FANCA deletions either by a sequence change or by epigenetic mechanisms, FANCA gene expression was analyzed in these samples. A real-time quantitative assay was developed to assess gene transcription for FANCA exons 19 and 20, which was a region known to be deleted in all four samples. The assay was carried out in the three samples with FANCA deletions from which RNA was available and in peripheral blood lymphocyte or bone marrow RNA derived from six healthy individuals, as well as in bone marrow and CD34-selected peripheral blood stem cells from three healthy controls. The results are shown in Figure 2 FANCA gene deletions in AML MD Tischkowitz et al deletions compared to normal controls (Student's t-test, onetailed, P ¼ 0.0048) and was also lower compared to nondeleted AML cases (Student's t-test, one-tailed, P ¼ 0.036). FANCA expression was higher in six out of nine nondeleted AML samples in comparison with normal controls. Comparable data were observed using ABL as the control gene (data not shown).
Discussion
The prevalence of FA in the general population is approximately 3 per million 14 and FANCA accounts for around two-thirds of cases. Using the Hardy-Weinberg equation, one can estimate the carrier frequency of FANCA mutations to be 0.28%. Previous studies have shown that deletions account for 40% of FANCA mutations, 28 so the carrier frequency of FANCA deletions can be estimated to be 0.11% in the general population. The number of FANCA deletion heterozygotes detected in this cohort of sporadic AML patients (4/101) is thus approximately 35 times the expected frequency of germline FANCA deletion mutations in the general population (exact binomial test, Po0.0001). The deletions could be germline or somatic mutations, but this could not be determined as the tumor samples were archival and the patients were no longer alive; of the three cases with deletions where clinical details were available, two (cases 63 and 65) died during induction and the third (case 83) went into remission for 3 months before relapsing.
Interestingly, three of the FANCA-deleted samples had monosomy 7, which is the most frequently reported cytogenetic abnormality in AMLs from cases of FA. 38 In addition to monosomy 7, all had loss or structural anomalies of chromosome 5 in the context of a highly complex karyotype (see Table 1 ). Such characteristics are usually associated with therapy-related leukemia particularly following exposure to alkylating agents. 39 It may be that these complex karyotypes are specifically associated with FANCA deletions or alternatively they may have facilitated detection of FANCA abnormalities in the neoplastic cells.
The FANCA deletions could be the result of large chromosomal deletions that may occur in AML, as would seem likely to be the case in samples 63 and 96 where all measured exons were half expected values and the flanking microsatellite markers were all homozygous. In the other samples, 65 and 83, the deletions were intragenic.
No mutations were detected in the other FANCA allele in these four samples by sequencing all FANCA exons and splice sites, but other mutations such as those affecting intronic splicing enhancers/silencers or creating cryptic splice sites cannot be excluded. Analysis of CpG island methylation in the promoter region of FANCA for epigenetic silencing did not reveal any evidence of methylation in the AML samples with FANCA deletions, or in a further 27 AML samples without a FANCA deletion. These data are consistent with the quantitative analysis of FANCA mRNA, which detected reduced FANCA expression in the deleted samples compared to the nondeleted AML samples and to the controls. If there is inactivation of only one FANCA allele in the deletion samples, one would expect less than a two-fold reduction in gene expression due to the presence of some nonmalignant cells. However, the reduction observed was approximately 2.4-fold relative to normal controls and approximately four-fold relative to nondeleted AML samples, which suggests that there may have been partial inactivation of the second FANCA allele in some of the deleted samples. Some of the variation in the degree of reduction could be due to differing proportions of normal and blast cells in each AML sample. The higher expression of FANCA in some AML samples may be a result of the increased expression of FANCA (and other FA genes) in rapidly dividing tissues. 40 Taken together, our data indicate heterozygous deletions of the FANCA gene are found in a small but significant proportion of sporadic AMLs. The study by Condie et al 22 reported one previously described FANCA mutation and four other nonconservative amino acid substitutions that were absent in controls. Thus, it is possible that five of 79 adult AML samples in that series were heterozygous for pathogenic FANCA mutations. However, none of the mutations reported in the study by Condie et al 22 were truncating. Our study did not test for point mutations in the primary mutation screen of the 101 AML samples, whereas Condie et al 22 did not screen for large deletions. Taken together, these two studies suggest that heterozygous mutation of the FANCA gene occurs in a significant proportion of sporadic AMLs. If the mutations identified in this study are indeed germ line, then heterozygous FANCA deletions may be considered to be low penetrance alleles for conferring AML risk. Evidence for a heterozygote effect has been provided by Djuzenova et al, 41 who used an alkaline single-cell gel electrophoresis (comet) assay to show that cells from FA heterozygotes that were exposed to X-rays had higher initial DNA damage rates and a prolonged DNA repair half-time compared to control cells. Also, Pearson et al 42 found that FA heterozygotes had higher mean rates of chromosomal aberrations following exposure to diepoxybutane than normal controls. These findings suggest that FA heterozygotes may have an impaired ability to maintain genomic integrity. This hypothesis has not been corroborated by epidemiological studies that failed to show an increased incidence of AML in FA families, 14, 15 although these were based on small numbers and were therefore underpowered. Alternatively, the mutations could be somatic with acquired dysfunction of FA proteins acting as a progression factor in MDS/AML. Haplo-insufficiency of an FA gene in a progenitor cell may promote genomic instability, which could result in further mutations and the evolution of a tumorigenic clone. 16 In fact, either a germline FA gene mutation or a somatic mutation in a stem cell may constitute a progression factor in a pathway that leads in some cases to chromosomal instability and cancer. 16, 26 The three cases with FANCA gene deletions in which diagnostic cytogenetics was available had a very complex karyotype, which is consistent with this hypothesis. Further studies looking at both tumor and germline DNA from sporadic AML cases are required to determine whether FANCA or other FA gene mutations represent germline or somatic mutations. This study also provides the rationale for a more extensive study; it will be interesting to establish whether abnormalities of the FA pathway are commonly implicated in cases of AML with adverse cytogenetics in which molecular mechanisms are currently poorly understood.
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